Edurant
by Johnson & Johnson
Edurant is a once-daily oral HIV medication available through the Johnson & Johnson Patient Assistance Program.
Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved as part of a complete HIV-1 treatment regimen for antiretroviral-naïve adults and adolescents (ages 12 and older, weighing at least 35 kg) with HIV-1 RNA ≤100,000 copies/mL at the start of treatment. It is taken once daily with a meal. Rilpivirine is also the active component in several combination HIV regimens including Complera, Odefsey, Juluca, and Cabenuva (the long-acting monthly injectable), making familiarity with it clinically important across treatment pathways.
Patient assistance programs
Johnson & Johnson Patient Assistance Program (J&J withMe)
Manufacturer PAP- Eligibility
- Uninsured or underinsured adults and adolescents (age 12+, ≥35 kg) with a valid Edurant prescription from a licensed U.S. healthcare provider who meet income requirements.
- Income limit
- Varies based on household size; generally ≤400% of Federal Poverty Level (FPL)
- Insurance
- Uninsured or underinsured
- How to apply
- Apply through ClariMeds — we handle all paperwork at no cost to you. Applications are submitted directly to J&J withMe on your behalf.
- Phone
- 1-800-652-6227
Need help applying?
ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.
See If You Qualify — Free